Robert Crowder
Overview
Explore the profile of Robert Crowder including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
1965
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lei J, Shao J, Zhang J, Iglesia M, Chan D, Cao J, et al.
Cell Rep
. 2018 Aug;
24(6):1434-1444.e7.
PMID: 30089255
RNA sequencing (RNA-seq) detects estrogen receptor alpha gene (ESR1) fusion transcripts in estrogen receptor-positive (ER) breast cancer, but their role in disease pathogenesis remains unclear. We examined multiple ESR1 fusions...
2.
Ma C, Sanchez C, Gao F, Crowder R, Naughton M, Pluard T, et al.
Clin Cancer Res
. 2016 Jan;
22(11):2650-8.
PMID: 26783290
Purpose: PI3K/AKT pathway activation is an important endocrine resistance mechanism in estrogen receptor-positive (ER(+)) breast cancer. After promising preclinical modeling of MK-2206, an allosteric pan-AKT inhibitor, with either estrogen deprivation...
3.
Wardell S, Ellis M, Alley H, Eisele K, VanArsdale T, Dann S, et al.
Clin Cancer Res
. 2015 May;
21(22):5121-5130.
PMID: 25991817
Purpose: Endocrine therapy, using tamoxifen or an aromatase inhibitor, remains first-line therapy for the management of estrogen receptor (ESR1)-positive breast cancer. However, ESR1 mutations or other ligand-independent ESR1 activation mechanisms...
4.
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al.
Cell Rep
. 2013 Sep;
4(6):1116-30.
PMID: 24055055
To characterize patient-derived xenografts (PDXs) for functional studies, we made whole-genome comparisons with originating breast cancers representative of the major intrinsic subtypes. Structural and copy number aberrations were found to...
5.
Ellis M, Ding L, Shen D, Luo J, Suman V, Wallis J, et al.
Nature
. 2012 Jun;
486(7403):353-60.
PMID: 22722193
To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy by...
6.
Ding L, Ellis M, Li S, Larson D, Chen K, Wallis J, et al.
Nature
. 2010 Apr;
464(7291):999-1005.
PMID: 20393555
Massively parallel DNA sequencing technologies provide an unprecedented ability to screen entire genomes for genetic changes associated with tumour progression. Here we describe the genomic analyses of four DNA samples...
7.
Ellis M, Lin L, Crowder R, Tao Y, Hoog J, Snider J, et al.
Breast Cancer Res Treat
. 2009 Oct;
119(2):379-90.
PMID: 19844788
Mutations in the alpha catalytic subunit of phosphoinositol-3-kinase (PIK3CA) occur in approximately 30% of ER positive breast cancers. We therefore sought to determine the impact of PIK3CA mutation on response...
8.
Ellis M, Gao F, Dehdashti F, Jeffe D, Marcom P, Carey L, et al.
JAMA
. 2009 Aug;
302(7):774-80.
PMID: 19690310
Context: Estrogen deprivation therapy with aromatase inhibitors has been hypothesized to paradoxically sensitize hormone-receptor-positive breast cancer tumor cells to low-dose estradiol therapy. Objective: To determine whether 6 mg of estradiol...
9.